NASDAQ:OBLN - Obalon Therapeutics Stock Price, Price Target & More

Obalon Therapeutics trades on the NASDAQ under the ticker symbol "OBLN."

Obalon Therapeutics Inc (NASDAQ:OBLN) announced its quarterly earnings results on Monday, March, 5th. The company reported ($0.60) EPS for the quarter, missing analysts' consensus estimates of ($0.48) by $0.12. The business earned $3.69 million during the quarter, compared to analysts' expectations of $3.88 million. Obalon Therapeutics had a negative return on equity of 102.17% and a negative net margin of 399.94%. View Obalon Therapeutics' Earnings History.

Obalon Therapeutics is scheduled to release their next quarterly earnings announcement on Wednesday, August, 1st 2018. View Earnings Estimates for Obalon Therapeutics.

5 Wall Street analysts have issued 12-month price objectives for Obalon Therapeutics' shares. Their forecasts range from $4.00 to $16.00. On average, they anticipate Obalon Therapeutics' share price to reach $9.25 in the next year. View Analyst Ratings for Obalon Therapeutics.

Some companies that are related to Obalon Therapeutics include SeaSpine (SPNE), Apollo Endosurgery (APEN), Alphatec (ATEC), Restoration Robotics (HAIR), Sensus Healthcare (SRTS), INVO Bioscience (IVOB), Arch Therapeutics (ARTH), Motus GI (MOTS), Invuity (IVTY), Neovasc (NVCN), SANUWAVE (SNWV), Spectral Medical (EDTXF), iCAD (ICAD), Repro-Med Systems (REPR) and CAS Medical Systems (CASM).

(OBLN) raised $75 million in an IPO on Thursday, October 6th 2016. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. UBS Investment Bank, Canaccord Genuity and Stifel acted as the underwriters for the IPO and BTIG was co-manager.

Media coverage about OBLN stock has trended somewhat positive on Sunday, according to Accern Sentiment Analysis. The research group identifies negative and positive media coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Obalon Therapeutics earned a coverage optimism score of 0.10 on Accern's scale. They also assigned headlines about the company an impact score of 47.61 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the next several days.

Obalon Therapeutics' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Tamarack Advisers LP (2.42%), Massachusetts Financial Services Co. MA (1.78%), C WorldWide Group Holding A S (1.41%), Tiverton Asset Management LLC (0.43%) and Granite Investment Partners LLC (0.27%). Company insiders that own Obalon Therapeutics stock include Kim P Kamdar, Matthew Norwood, Neil Drake and William J Plovanic. View Institutional Ownership Trends for Obalon Therapeutics.

OBLN stock was sold by a variety of institutional investors in the last quarter, including Massachusetts Financial Services Co. MA, Tamarack Advisers LP, Granite Investment Partners LLC, C WorldWide Group Holding A S and Tiverton Asset Management LLC. View Insider Buying and Selling for Obalon Therapeutics.

Shares of OBLN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of OBLN stock can currently be purchased for approximately $2.54.

Obalon Therapeutics has a market capitalization of $44.64 million and generates $9.91 million in revenue each year. The company earns $-34,760,000.00 in net income (profit) each year or ($2.08) on an earnings per share basis. Obalon Therapeutics employs 113 workers across the globe.

Obalon Therapeutics' mailing address is 5421 Avenida Encinas Suite F, Carlsbad CA, 92008. The company can be reached via phone at 760-795-6558 or via email at [email protected]